Skip to main content
. 2022 Mar 8;14:40. doi: 10.1186/s13195-022-00981-1

Table 2.

Adverse events description. Treatment-emergent adverse events (CTCAE version number) which occurred during treatment or up to 30 days after the end of therapy. The occurrence of each adverse event is listed as well as the total number of patients affected as some patients might have experienced the same adverse event multiple times over the course of therapy

N = 10 patients Number of events by grade Number (percentage) of participants
Grade 1 Grade 2
Delirium with frontal microbleed 1 1 (10%)
Fatigue 2 2 (20%)
Back pain 1 1 (10%)
Dandruff 1 1 (10%)
Prurit 1 1 (10%)
Asymptomatic low blood pressure 1 1 (10%)
Right hand sensitive deficit 1 1 (10%)
Headaches (intensity range on a visual scale, 2–4/10) 2 2 (20%)
Diarrhea 1 1 (10%)
Abdominal pain 2 1 (20%)